When Bayer AG voluntarily withdrew Baycol (cerivastatin) from the worldwide market on 8 August 2001, the company described it as a precaution against a rising “reporting rate” of muscle injury; the documented record shows that the latecomer statin had already been associated with fatal rhabdomyolysis at roughly forty to fifty times the rate of its competitors, a hazard that was foreseeable from its known pharmacology and visible in adverse-event data well before the recall. Cerivastatin, the sixth statin to reach the U.S. market and approved by the Food and Drug Administration in June 1997, was promoted as a potent, low-dose entrant in an already crowded class. It captured slightly under 4 percent of the U.S. statin market — and yet, by the FDA’s own count at withdrawal, it accounted for 31 American deaths from rhabdomyolysis, a condition in which skeletal muscle disintegrates, floods the bloodstream with myoglobin, and shuts down the kidneys.
The gap between promise and reality was not a matter of rare bad luck. In an analysis by FDA scientists, the relative reporting rate of fatal rhabdomyolysis was on the order of forty times higher for cerivastatin than for the other approved statins; for all rhabdomyolysis, fatal and nonfatal, the figure was roughly fifty-four times higher. The danger was concentrated and predictable: it rose with the 0.8 mg high dose Bayer had introduced to compete on potency, rose in elderly patients, and rose catastrophically when cerivastatin was combined with gemfibrozil, a fibrate that interfered with the drug’s clearance. Twelve of the 31 U.S. deaths involved that very combination — a combination Bayer had contraindicated on the label, but which physicians prescribed in numbers the warning failed to suppress.
The withdrawal came only when the body count made the signal undeniable. The verdict here is therefore plain at the outset: an approved cholesterol drug holding a minority share of its market produced a disproportionate share of its class’s fatal harm, because a known drug-interaction hazard and an aggressive high-dose strategy were allowed to reach roughly six million patients while the contraindication label substituted for the market action the data warranted.
What followed was a transatlantic litigation reckoning. Bayer faced on the order of 7,800 product-liability suits in the United States alone — a figure that grew past 12,000 — and ultimately paid well over $1 billion to settle claims, while internal documents pried loose in discovery showed company scientists had flagged the gemfibrozil danger and the rising death reports before the recall. Baycol became the standard cautionary case for how a “me-too” drug competing on potency can convert a known interaction into mass casualties.
When Hoffmann-La Roche pulled Posicor from the U.S. market on 8 June 1998, just under a year after the Food and Drug Administration approved it in June 1997, the company framed the move as a precaution against drug interactions; the documented record shows that the molecule’s defining pharmacology — potent, mechanism-based inhibition of the liver enzyme cytochrome P450 3A4 — made it a hazard the moment it was co-prescribed with the ordinary medicines a hypertension or angina patient already took. Posicor (mibefradil), marketed as a first-in-class blocker of low-voltage T-type calcium channels, was promoted as a cleaner, more selective antihypertensive. It instead became one of the fastest major drug withdrawals of its era, undone not by a flaw in what it did to the heart but by what it did to the metabolism of dozens of unrelated drugs.
The gap between promise and harm was structural, not incidental. By slowing CYP3A4 — the enzyme that clears a large fraction of all prescription drugs — mibefradil let co-administered medicines accumulate to toxic levels. Statins such as simvastatin built up until muscle dissolved into the bloodstream (rhabdomyolysis), threatening the kidneys; antiarrhythmics, certain antihistamines, calcium-channel blockers and beta-blockers stacked into bradycardia, shock, and cardiac arrest. By the time of withdrawal more than 25 medications were known to be dangerous in combination with Posicor, and the drug was being taken by almost 200,000 Americans and nearly twice that number worldwide.
The verdict here is therefore plain at the outset. This was not a slow-burn safety signal suppressed over years, as with some withdrawals; it was a foreseeable consequence of the drug’s own measured pharmacokinetics, surfacing within months of launch. A particularly damning cluster, reported in JAMA in 1998, described patients who — following the very label advice to switch off Posicor onto another agent — went into shock within twelve hours, one of whom died, because mibefradil’s enzyme inhibition persisted for days after the last dose.
The reckoning was swift rather than litigious. Roche withdrew the drug globally, the FDA documented the action in the Federal Register, and the episode became a standard teaching case in clinical pharmacology: the canonical example of how a single potent CYP3A4 inhibitor can convert routine co-prescription into mass interaction risk, and how a list of contraindicated drugs that keeps growing after launch is itself the warning.
When Joseph Califano, Secretary of Health, Education and Welfare, signed the order suspending phenformin on 25 July 1977, he was invoking a power Congress had granted the Food and Drug Administration fifteen years earlier and which no official had ever used: the declaration that an approved medicine was an “imminent hazard to the public health.” Phenformin (phenethylbiguanide), synthesized in 1957 by a team including Seymour Shapiro at the U.S. Vitamin Corporation and marketed in the United States from 1959 by Ciba-Geigy as DBI, had been prescribed to control adult-onset diabetes for nearly two decades. It was withdrawn not because it failed to lower blood sugar — it did that adequately — but because it could quietly poison the body with lactic acid, a complication that killed roughly one of every two patients it reached.
The gap between the promise and the harm was the gap between a surrogate benefit and a survival outcome. Phenformin reliably reduced glycemia, the number physicians could see on a chart; what it did not reliably do was keep patients alive. The biguanide’s mechanism — pushing cellular metabolism toward anaerobic glycolysis — produced excess lactate, and in patients with even modest kidney or heart impairment that lactate could accumulate into a metabolic catastrophe. Phenformin-associated lactic acidosis ran at roughly 40 to 64 cases per 100,000 patient-years, and once it occurred it was fatal in approximately half of cases. The drug treated a chronic disease by trading a visible, manageable problem for an occasional, lethal one.
The verdict was therefore plain long before the suspension. As early as 1959 — the same year U.S. marketing began — the literature linked biguanides to lactic acidosis. In 1971 the federally funded University Group Diabetes Program (UGDP) terminated its phenformin arm after finding excess total and cardiovascular mortality, roughly double that of the placebo and insulin groups combined. By October 1976 the FDA’s own Endocrinology and Metabolism Advisory Committee had recommended removal. The harm sat in the published record for years while ~385,000 Americans were still taking the drug in 1977.
What forced the cord was not the agency but a consumer group and a lawyer’s petition. Ralph Nader’s Health Research Group petitioned for suspension on 22 April 1977; Califano acted in July; the drug was off the U.S. market by 15 November 1978. The episode became the founding precedent for emergency drug suspension, the cautionary prologue to its safer sister biguanide metformin, and the textbook case of how a medicine can be effective on the metric it was sold on and still be a net killer.